Literature DB >> 9062584

An update of HNPCC (Lynch syndrome).

H T Lynch1, T Smyrk, J Lynch.   

Abstract

Genetic epidemiology studies of colorectal cancer (CRC) can identify persons who are at inordinately high risk and who thereby might benefit from targeted early detection and primary prevention programs, inclusive of prophylactic surgery in selected cases. The discipline of molecular genetics has identified germline mutations that include APC in familial adenomatous polyposis (FAP) and mutator genes, namely MSH2, MLH1, PMS1, and PMS2 in hereditary nonpolyposis colorectal cancer (HNPCC). These discoveries have significantly enhanced our ability to identify individuals whose cancer destiny can literally be determined at birth. This review updates HNPCC's differential diagnosis, heterogeneity, tumor spectrum, newly found evidence of accelerated colonic adenoma to CRC, survival advantage, and currently available surveillance and management programs. Emphasis has been on how knowledge of the genetics and natural history of HNPCC can be used effectively to promote early diagnosis or prevention of cancer.

Entities:  

Mesh:

Year:  1997        PMID: 9062584     DOI: 10.1016/s0165-4608(96)00290-7

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  33 in total

Review 1.  DNA mismatch repair genes and colorectal cancer.

Authors:  J M Wheeler; W F Bodmer; N J Mortensen
Journal:  Gut       Date:  2000-07       Impact factor: 23.059

2.  Direct selection for mutators in Escherichia coli.

Authors:  J H Miller; A Suthar; J Tai; A Yeung; C Truong; J L Stewart
Journal:  J Bacteriol       Date:  1999-03       Impact factor: 3.490

3.  Hereditary cancer-associated missense mutations in hMSH6 uncouple ATP hydrolysis from DNA mismatch binding.

Authors:  Jennifer L Cyr; Christopher D Heinen
Journal:  J Biol Chem       Date:  2008-09-11       Impact factor: 5.157

4.  Cancer risk assessment by rural and Appalachian family medicine physicians.

Authors:  Kimberly M Kelly; Margaret M Love; Kevin A Pearce; Kyle Porter; Mary A Barron; Michael Andrykowski
Journal:  J Rural Health       Date:  2009       Impact factor: 4.333

5.  Humans accumulate microsatellite instability with acquired loss of MLH1 protein in hematopoietic stem and progenitor cells as a function of age.

Authors:  Jonathan Kenyon; Pingfu Fu; Karen Lingas; Emily Thomas; Anshul Saurastri; Gabriela Santos Guasch; David Wald; Stanton L Gerson
Journal:  Blood       Date:  2012-06-26       Impact factor: 22.113

Review 6.  Genetic susceptibility to non-polyposis colorectal cancer.

Authors:  H T Lynch; A de la Chapelle
Journal:  J Med Genet       Date:  1999-11       Impact factor: 6.318

7.  A phylogenomic study of the MutS family of proteins.

Authors:  J A Eisen
Journal:  Nucleic Acids Res       Date:  1998-09-15       Impact factor: 16.971

8.  Inherited colorectal cancer syndromes.

Authors:  C Neal Ellis
Journal:  Clin Colon Rectal Surg       Date:  2005-08

9.  Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability.

Authors:  Asad Umar; C Richard Boland; Jonathan P Terdiman; Sapna Syngal; Albert de la Chapelle; Josef Rüschoff; Richard Fishel; Noralane M Lindor; Lawrence J Burgart; Richard Hamelin; Stanley R Hamilton; Robert A Hiatt; Jeremy Jass; Annika Lindblom; Henry T Lynch; Païvi Peltomaki; Scott D Ramsey; Miguel A Rodriguez-Bigas; Hans F A Vasen; Ernest T Hawk; J Carl Barrett; Andrew N Freedman; Sudhir Srivastava
Journal:  J Natl Cancer Inst       Date:  2004-02-18       Impact factor: 13.506

10.  Frequency of extra-colonic tumors in hereditary nonpolyposis colorectal cancer (HNPCC) and familial colorectal cancer (FCC) Brazilian families: An analysis by a Brazilian Hereditary Colorectal Cancer Institutional Registry.

Authors:  Fáblio Oliveira Ferreira; Claudia Cristina Napoli Ferreira; Benedito Mauro Rossi; Wilson Toshihiko Nakagawa; Samuel Aguilar; Erika Maria Monteiro Santos; Marcelo Leite Vierira Costa; Ademar Lopes
Journal:  Fam Cancer       Date:  2004       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.